Education
About Us
Working with TipRanks
Follow Us
Opus Genetics, Inc. (IRD)
:IRD
IRD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $2.18
Previous CloseN/A
Volume154.21K
Average Volume (3M)270.73K
Market Cap
$34.97M
Enterprise Value$26.09M
Total Cash (Recent Filing)$30.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
May 09, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.99
Shares Outstanding47,183,823
10 Day Avg. Volume221,453
30 Day Avg. Volume270,725
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.75
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$7.33Price Target Upside890.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial positive visual acuity gains have been observed in patients with advanced LCA5 disease, indicating potential for clinical advancement.
PartnershipsThe partnership for phentolamine ophthalmic solution, funded by Viatris, adds diversity to the company’s pipeline and offers multiple upcoming data catalysts.
Regulatory ApprovalsA Special Protocol Assessment agreement with the FDA for the Phase 3 LYNX-2 trial aligns agency expectations for treating vision issues under low light conditions.
Bears Say
Investor SentimentSome investors believe that a new therapy will need to show significant vision improvement (and not just prevention of worsening) to garner adoption.
---
Ownership Overview
8.83% Insiders
2.78% Mutual Funds
6.77% Other Institutional Investors
79.37% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
IRD FAQ
What was Opus Genetics, Inc.’s price range in the past 12 months?
Opus Genetics, Inc. lowest stock price was $0.65 and its highest was $2.18 in the past 12 months.
What is Opus Genetics, Inc.’s market cap?
Opus Genetics, Inc.’s market cap is $34.97M.
When is Opus Genetics, Inc.’s upcoming earnings report date?
Opus Genetics, Inc.’s upcoming earnings report date is May 09, 2025 which is in 16 days.
How were Opus Genetics, Inc.’s earnings last quarter?
Opus Genetics, Inc. released its earnings results on Mar 06, 2025. The company reported -$1.27 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$1.025.
Is Opus Genetics, Inc. overvalued?
According to Wall Street analysts Opus Genetics, Inc.’s price is currently Undervalued.
Does Opus Genetics, Inc. pay dividends?
Opus Genetics, Inc. does not currently pay dividends.
What is Opus Genetics, Inc.’s EPS estimate?
Opus Genetics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Opus Genetics, Inc. have?
Opus Genetics, Inc. has 47,183,823 shares outstanding.
What happened to Opus Genetics, Inc.’s price movement after its last earnings report?
Opus Genetics, Inc. reported an EPS of -$1.27 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of Opus Genetics, Inc.?
Currently, no hedge funds are holding shares in IRD
---
Opus Genetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (890.54% Upside)
$7.33 (890.54% Upside)
Blogger Sentiment
Bullish
IRD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $97.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.22%
12-Months-Change
Fundamentals
Return on Equity
-203.19%
Trailing 12-Months
Asset Growth
-31.62%
Trailing 12-Months
Company Description
Opus Genetics, Inc.
Opus Genetics (IRD) is a biotechnology company focused on developing gene therapies for inherited retinal diseases. The company operates within the biopharmaceutical sector, concentrating on creating innovative treatments aimed at restoring vision for patients affected by genetic eye disorders. Its core products are gene therapy solutions that target specific genetic mutations responsible for retinal diseases.
---
IRD Stock 12 Month Forecast
Average Price Target
$7.33
▲(890.54% Upside)
Technical Analysis
Spero Therapeutics
―
Repare Therapeutics
―
Prelude Therapeutics
―
AN2 Therapeutics, Inc.
―
Best Analysts Covering IRD
1 Year
1 Year Success Rate
6/22 ratings generated profit
1 Year Average Return
-10.46%
reiterated a buy rating 22 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -10.46% per trade.
---